[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Sheikh Zayed Federal Postgraduate Medical Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100643793","phase-4-comparison-of-effectiveness-and-safety-of-tofacitinib-versus-upadacitinib-as-add-on-to-methotrexate-in-rheumatoid-arthritis-100643793",false,"NCT07636057","Comparison of Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis","Effectiveness and Safety of Tofacitinib Versus Upadacitinib as Add-on to Methotrexate in Rheumatoid Arthritis; Comparative Clinical Study","Inclusion Criteria:\n\n* • Adult patients aged ≥18 years, regardless of gender\n\nExclusion Criteria:\n\n* • Other autoimmune rheumatic disorders (SLE, psoriatic arthritis, AS, etc.)\n\n  * Administration of any biologic DMARD in the previous three months\n  * History of a serious infection (e.g., active tuberculosis or sepsis)\n  * Previous or existing history of recurrent infections or immunosuppressive status\n  * History of any malignancy in the last five years.\n  * Current chemotherapy, radiotherapy or intake of any genotoxic drug\n  * Severe liver impairment (e.g., ALT\u002FAST \\>3× ULN)\n  * Severe renal impairment (e.g., estimated GFR \\\u003C30 mL\u002Fmin)\n  * Severe Haematological Abnormalities: Hb \\\u003C8 g\u002FdL, TLC \\\u003C3,000 \u002Fmm³, Platelets \\\u003C100,000 \u002Fmm³\n  * Past or present deep vein thrombosis or pulmonary embolism\n  * Pregnant or lactating women\n  * Women of reproductive age who are not practicing adequate contraception measures","ALL","20 Years","55 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of this interventional study is to learn, whether Tofacitinib or upadacitinib is more effective in treating the patients of Rheumatoid Arthritis. It will also learn about the safety of these two agents. The main questions it aims to answer are:\n\n* Which JAK inhibitor (Tofacitinib or Upadacitinib) is more effective to improve the disease activity of Rheumatoid arthritis in Pakistani population?\n* What is the Disease Activity scores, ESR, CRP, RA factor level of patients?\n* What are the side effects of both drugs, during the study time?\n\nParticipants:\n\n* Of Group A will be taking 5mg Tofacitinib oral daily for 6 months along with 25mg of once weekly dose of oral Methotrexate, whereas of Group B will be taking 15mg Upadacitinib oral daily for 6 months along with 25mg of once weekly dose of oral methotrexate.\n* Will Visit the clinic once at 3 months and then 6 months for checkups and tests\n* Will Keep a diary of any infection, treatment taken, duration of infection\n* Will inform the researcher about any unusual side effect during the study",[27],"Rheumatoid Arthritis (RA)","NOT_YET_RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":21},"2026-07-05",{"date":36,"type":21},"2027-05-10",{"name":38,"class":39},"Sheikh Zayed Federal Postgraduate Medical Institute","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100625360","management-of-epistaxis-comparing-nasal-packing-versus-greater-palatine-foramen-block-100625360","NCT07421622","Management of Epistaxis Comparing Nasal Packing Versus Greater Palatine Foramen Block","A Pilot Randomized Controlled Trial in Management of Epistaxis Comparing Nasal Packing Versus Greater Palatine Foramen Block","ANPvsGPF block","Inclusion Criteria:\n\n* Presentation with active anterior epistaxis\n* Failure of initial conservative measures (e.g., nasal compression and topical vasoconstrictors)\n* Ability to provide informed consent and those who consent for the study.\n\nExclusion Criteria:\n\n* Suspected or confirmed posterior epistaxis\n* Known bleeding disorders or platelet count \\\u003C50,000\u002Fmm³\n* Use of anticoagulants with supratherapeutic INR\n* Known allergy to local anaesthetic agents","18 Years","70 Years",{"count":51,"type":21},40,[53],"NA","The goal of this pilot randomized controlled trial is to compare pain relief efficacy while using nasal packing versus greater palatine foramen block (GPFB) in the management of acute episodes of epistaxis. The main questions it aims to answer are: Does GPFB have less potential to inflict pain when dealing with hemostasis with epistaxis, utilizing a pre-validated 10-point visual analog scale (VAS)? Was hemostasis management more effective in either technique? Researchers will compare anterior nasal packing to greater palatine foramen block using 2% xylocaine with adrenaline.\n\nPatients will receive any of the hemostatic interventions at the time of the acute epistaxis episode.\n\nThe questionnaire will be administered 24 hours post-intervention.",[56,57],"Epistaxis Nosebleed","Greater Palatine Foramen",[59],"epistaxis","2026-02-20",{"date":62,"type":32},"2026-02-24",{"date":64,"type":21},"2026-03-01",{"date":66,"type":21},"2027-02-28",{"name":38,"class":39},{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":22,"phases":78,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100613992","phase-3-comparison-of-outcomes-between-topical-minoxidil-versus-oral-minoxidil-for-the-treatment-of-androgenetic-alopecia-100613992","NCT07273799","Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia","mina","Inclusion Criteria:\n\n* Patients with androgenic alopecia Norwood-Hamilton class 2-6 in males and Sinclair class 2-5 in females\n* History of androgentic alopecia for at least 1 year\n* 18 to 50 years of age\n* Willing to provide informed consent\n* Willing to not use any other hair loss treatment during the treatment period\n\nExclusion Criteria:\n\n* History of cardiovascular disease\n* Use of some other hair restoration therapy in the past 6 months such as minoxidil, finasteride or PRP\n* Presence of other causes of alopecia (e.g., alopecia areata, scarring alopecia).\n* Pregnant and lactating females\n* Previous Hair Transplantation\n* Patients with a known hypersensitivity to the study drug or class of study drug\n* Patients with co-morbid conditions like chronic liver disease, chronic kidney disease, neurological or psychiatric disorders\n* Presence of any other autoimmune disease (especially thyroid disease)","50 Years",{"count":77,"type":21},200,[79],"PHASE3","To compare the outcome of topical minoxidil 5% spray versus oral minoxidil 2.5 mg tablet for the treatment of androgenetic alopecia in males and females. Outcomes include efficacy of the treatment, measured by reduction in hair shedding, improvement in hair density and new hair growth as assessed by physican and patient assessment as well as safety, defined as incidence and severity of adverse events over a treatment period of 6 months",[82],"Androgenic Alopecia",[82,84],"Minoxidil","2025-12-05",{"date":87,"type":32},"2025-12-10",{"date":89,"type":21},"2025-12-20",{"date":91,"type":21},"2026-06-01",{"name":38,"class":39},""]